Navigation Links
Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gilead's Sofosbuvir and Janssen/Medivir's Simeprevir
Date:11/21/2013

EXTON, Pa., Nov. 21, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, following the launches of Gilead's sofosbuvir and Janssen/Medivir's simeprevir in the United States, currently marketed triple (Vertex's Incivek- and Merck's Victrelis-containing regimens) and dual therapy hepatitis C virus (HCV) regimens will lose market share to sofosbuvir-and simeprevir-based regimens. When asked about treatment practices in the next six months, surveyed physicians plan to treat 17 percent of their genotype 1 and 21 percent of their actively treated genotype 2/3 HCV patients with a sofosbuvir- and/or simeprevir-containing regimen.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The report entitled TreatmentTrends®: Hepatitis C Virus (US), Wave 2 also finds that the majority of surveyed physicians reported, unaided, that they are currently warehousing HCV patients in anticipation of new therapies, with nearly 30 percent of this warehousing specifically attributed to waiting for access to sofosbuvir/polymerase inhibitors. While most surveyed physicians are warehousing treatment-naive and treatment-experienced patients as they wait for the approval of simeprevir, sofosbuvir and/or other interferon-free therapy options, only 12 percent of surveyed physicians indicated they are satisfied with currently approved therapies.

"In anticipation of availability of new directly-acting antivirals, the shift in the HCV treatment paradigm is already apparent," said BioTrends Research Group Analyst Sandra Renz. "With the imminent approval of simeprevir and sofosbuvir – agents offering po
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Current Regulatory Expectations Affecting the Validation of Reusable Medical Devices is Subject of Dec. 4th Seminar in Boston
2. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
3. Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists Top Unmet Need in Mild to Moderate Alzheimers Disease
4. OPTIMIZERx Corporation Announces the Resignation of the Companys Current CEO & Chairman Mr. Shadron L. Stastney
5. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
6. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
7. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
8. Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
9. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
10. Hepatitis C Drug Market: Forecasts for 9 Countries, Players (Current and Future) Analysis in New Research Reports
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... 29, 2011 UBM Canon,s leading brand, Japan Medical Design ... the launch of its new Japanese-language website with enhanced content and ... website allows users to find the resources and information they ... Editor-in-Chief, EMDT , JMDMT , and CMDM ...
... June 29, 2011 Cayenne Medical, Inc., a private ... II Meniscal Repair System, its second generation device for ... on display at the 2011 American Orthopaedic Society for ... CA.   Tal David, MD, orthopedic sports ...
Cached Medicine Technology:UBM Canon Announces New Japanese-Language Website for Japan Medical Design & Manufacturing Technology: www.jmdmt.com 2Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System 2
(Date:8/30/2015)... ... August 30, 2015 , ... Lizzie’s Lice Pickers , a company ... The company is currently offering lice head checks for just $10, which is a ... a 10% discount on their lice treatment products. “With kids returning to school, it ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... Jeff Fernandez will lead the expansion of global cosmeceutical and skin care brands. ... experience having spent the last 25 years working in operations, purchasing and management ...
(Date:8/29/2015)... ... 30, 2015 , ... Electronic Informed Consent for Clinical Trials:, ... EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed consent is ... Clinical trial sites can now use audio, video and interactivity to educate participants ...
(Date:8/29/2015)... Irvine, CA (PRWEB) , ... August 29, 2015 , ... ... on a mission. His mission is to increase acceptance of the chiropractic field ... pain medications that further debilitate them. Although Chiropractic was made available to the ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... environmental factors like sunlight and cigarette smoke have discovered how ... to tolerate the DNA damage that leads to cancer and ... protein called DNA polymerase eta (Pol eta) and accompanies it ... When Pol eta is not present, alternative error-prone polymerases ...
... CINCINNATI--Emergency medicine researchers with the University of Cincinnati (UC) ... but dangerous condition in the emergency room. Pulmonary ... which a blood clot, usually from the legs, travels ... artery. But the most common way of testing for ...
... be made from some of the same parts used ... a way to measure the growth and drug susceptibility ... microscope. The new biosensor promises to speed treatment ... Richard Smalley Distinguished University Professor of Chemistry, Physics and ...
... at The University of Nottingham have brought cancer cells back ... The discovery could form a powerful new technology platform for ... Breast cancer is diagnosed in about 1.4 million women ... from the disease. A common cause of cancer is when ...
... This release is available in French . ... Ph. D student in biology at Universit du Qubec ... and Adjunct Professor Elsy Edouard, UQAM, Department of Biological ... in research on B-cell acute lymphocytic leukemia, a disease that ...
... the last few years, researchers have used a type of ... help them map changes in blood flow in the brain ... way to analyze fMRI data, which could improve is reported ... Design . Scientists have known since the 1890s that ...
Cached Medicine News:Health News:Chaperone enzyme provides new target for cancer treatments 2Health News:'Selective strategy' recommended for CT scans in emergency departments 2Health News:See how they grow: Monitoring single bacteria without a microscope 2Health News:See how they grow: Monitoring single bacteria without a microscope 3Health News:Scientists bring cancer cells back under control 2Health News:Discovery of a gene associated with a leukemia mostly affecting children 2Health News:Functional boost for magnetic resonance imaging 2
Convenience, Protection, Comfort and Security -- FirstChoice pouches are your product of choice if you are looking for the convenience of a one-piece pouch that is either cut-to-fit or pre-cut to you...
Inquire...
Superior comfort and flexibility are achieved through the revolutionary air pocket technology in the dimpled, ultra-thin SoftFlex skin barrier along with a discreet pouch shape and size....
Inquire...
Medicine Products: